Grindeks Group has announced a significant expansion of its services, introducing Contract Development and Manufacturing Organization (CDMO) and out-licensing offerings. This strategic shift occurs under the leadership of the company’s new CEO and aims to leverage unused capacity identified across its manufacturing facilities.
The company, which has spent the past decade focusing primarily on its own brand portfolio, conducted a comprehensive review of its manufacturing sites in Latvia, Estonia, and Slovakia. This assessment revealed that certain facilities possess equipment and production capabilities that can support external partnerships. Specifically, Grindeks identified 24/7 production units that can be utilized for broader applications, enhancing its operational versatility.
Grindeks’ experience collaborating with other CDMOs has provided valuable insights into the flexibility and efficiency these partnerships can offer. The company recognizes the complexity involved in pharmaceutical development and manufacturing, which positions them well to assist collaborators with their needs.
The newly launched CDMO services will encompass development, analytical, and Good Manufacturing Practice (GMP) manufacturing support for both active pharmaceutical ingredients (APIs) and finished dosage forms. These services will facilitate projects from early research stages through to comprehensive GMP production, ensuring that partners have access to the necessary resources at every step.
In addition to CDMO services, Grindeks will provide ready-to-file dossiers and marketing authorization packages tailored for the European Union and international markets. These comprehensive packages are designed to assist companies in navigating regulatory pathways, equipped with established documentation to streamline the process.
By embracing this strategic expansion, Grindeks Group aims to enhance its collaboration with pharmaceutical partners, offering them greater access to its capabilities and infrastructure. The initiative is expected to foster stronger relationships within the industry, ultimately benefiting both Grindeks and its external partners as they work towards advancing innovative pharmaceutical products.
With this strategic pivot, Grindeks is positioning itself as a key player in the CDMO landscape, ready to meet the evolving demands of the pharmaceutical sector.
